Tag: Nms treatment

While the mortality rate for Neuroleptic Malignant Syndrome (NMS) has decreased significantly over the years due to improved recognition, it remains a serious and potentially fatal condition. The management strategy primarily revolves around immediate supportive care, but specific medications are often required to reverse NMS symptoms and target its underlying pathophysiology.

According to a 2024 study in the *New England Journal of Medicine*, neuroleptic malignant syndrome (NMS) remains a potentially fatal condition triggered by dopamine-blocking agents. While there is no single, universally agreed-upon **what is the drug of choice for treatment of neuroleptic malignant syndrome?**, management centers on immediate discontinuation of the causative agent and aggressive supportive care. In severe cases, specific medications like dantrolene and bromocriptine are often employed, though evidence for their definitive efficacy is limited.

While overall mortality rates have decreased, neuroleptic malignant syndrome (NMS) remains a life-threatening, albeit rare, adverse drug reaction. The cornerstone of treatment involves supportive care, but for the severe muscle rigidity that characterizes the syndrome, a specific muscle relaxant is often necessary. A primary muscle relaxant used for neuroleptic malignant syndrome is dantrolene, although its role and effectiveness, especially in combination therapy, is still debated.